Search

Your search keyword '"Pierre-Regis Burgel"' showing total 6 results
Start Over Author "Pierre-Regis Burgel" Topic pulmonary and respiratory medicine
6 results on '"Pierre-Regis Burgel"'

1. Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand

Author

Adèle Coriati, Xiayi Ma, Jenna Sykes, Sanja Stanojevic, Rasa Ruseckaite, Lydie Lemonnier, Clémence Dehillotte, Jan Tate, Catherine Ann Byrnes, Scott C Bell, Pierre Regis Burgel, and Anne L Stephenson

Subjects
Pulmonary and Respiratory Medicine
Abstract

BackgroundLife expectancy for people with cystic fibrosis (CF) varies considerably both within and between countries. The objective of this study was to compare survival among countries with single-payer healthcare systems while accounting for markers of disease severity.MethodsThis cohort study used data from established national CF registries in Australia, Canada, France and New Zealand from 2015 to 2019. Median age of survival for each of the four countries was estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to compare risk of death between Canada, France and Australia after adjusting for prognostic factors. Due to low number of deaths, New Zealand was not included in final adjusted models.ResultsBetween 2015 and 2019, a total of 14 842 people (3537 Australia, 4434 Canada, 6411 France and 460 New Zealand) were included. The median age of survival was highest in France 65.9 years (95% CI: 59.8 to 76.0) versus 53.3 years (95% CI: 48.9 to 59.8) for Australia, 55.4 years (95% CI: 51.3 to 59.2) for Canada and 54.8 years (95% CI: 40.7 to not available) for New Zealand. After adjusting for individual-level factors, the risk of death was significantly higher in Canada (HR 1.85, 95% CI: 1.48 to 2.32; pInterpretationWe observed significantly higher survival in France compared with countries with single-payer healthcare systems. The median age of survival in France exceeded 60 years of age despite having the highest proportion of underweight patients which may be due to differences in availability of transplant.

Published
2022
Full Text
View/download PDF

2. 2022 Update of indications and contraindications for lung transplantation in France

Author

Jérôme Le Pavec, Christophe Pison, Sandrine Hirschi, Vincent Bunel, Pierre Mordant, Olivier Brugière, Morgan Le Guen, Anne Olland, Benjamin Coiffard, Benjamin Renaud-Picard, Adrien Tissot, Geoffrey Brioude, Raphaël Borie, Bruno Crestani, Gaétan Deslée, Sandrine Stelianides, Hervé Mal, Armelle Schuller, Loïc Falque, Gwenaëlle Lorillon, Abdellatif Tazi, Pierre Regis Burgel, Dominique Grenet, Sandra De Miranda, Anne Bergeron, David Launay, Vincent Cottin, Hilario Nunes, Dominique Valeyre, Yurdagul Uzunhan, Grégoire Prévot, Olivier Sitbon, David Montani, Laurent Savale, Marc Humbert, Elie Fadel, Olaf Mercier, Jean François Mornex, Gaëlle Dauriat, Martine Reynaud-Gaubert, Université Paris-Sud - Paris 11 (UP11), Hôpital Marie-Lannelongue, Centre Hospitalier Universitaire [Grenoble] (CHU), Les Hôpitaux Universitaires de Strasbourg (HUS), CIC Hôpital Bichat, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pneumologie [Hôpital Foch], Hôpital Foch [Suresnes], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Hôpital Nord [CHU - APHM], unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) (U1064 Inserm - CR2TI), Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service des maladies respiratoires et allergiques [CHU Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de réadaptation [Achères] (IdR), Service de Chirurgie Thoracique, CHU Strasbourg-Nouvel Hôpital Civil, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Service de pneumologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpitaux Universitaires de Genève (HUG), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Physiologie de l'Insecte : Signalisation et Communication (PISC), Institut National de la Recherche Agronomique (INRA)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National Agronomique Paris-Grignon (INA P-G), Hôpital Avicenne [AP-HP], Centre hospitalier Saint-Joseph [Paris], Pôle Clinique des Voies respiratoires [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de pneumologie [CHU Bicêtre], Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay, Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Groupe Hospitalier Paris Saint-Joseph (hpsj), and Aix Marseille Université (AMU)

Subjects
Pulmonary and Respiratory Medicine, High emergency allocation program, [SDV]Life Sciences [q-bio], Lung transplantation contraindications, Lung transplantation indications, Candidate selection
Abstract

International audience; Lung transplantation (LTx) is a steadily expanding field. The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient selection, combined with multifaceted efforts to overcome challenges raised by the surgical procedure, perioperative care, and long-term medical complications. One consequence has been a pruning away of contraindications over time, which has, in some ways, complicated the patient selection process. The Francophone Pulmonology Society (Société de Pneumology de Langue Française, SPLF) set up a task force to produce up-to-date working guidelines designed to assist pulmonologists in managing end-stage respiratory insufficiency, determining which patients may be eligible for LTx, and appropriately timing LTx-center referral. The task force examined the most recent literature and evaluated the risk factors that limit patient survival after LTx. Ideally, the objectives of LTx are to prolong life while also improving quality of life. The guidelines developed by the task force apply to a limited resource and are consistent with the ethical principles described below.

Published
2023
Full Text
View/download PDF

3. New concepts in antimicrobial resistance in cystic fibrosis respiratory infections

Author

Pavel Drevinek, Rafael Canton, Helle Krogh Johansen, Lucas Hoffman, Tom Coenye, Pierre-Regis Burgel, and Jane C Davies

Subjects
Pulmonary and Respiratory Medicine, Cystic Fibrosis, Biofilm, Microbial Sensitivity Tests, Antimicrobial resistance, Pathoadaptation, Resistome, Anti-Bacterial Agents, Pseudomonas aeruginosa, Drug Resistance, Bacterial, Pediatrics, Perinatology and Child Health, Medicine and Health Sciences, Humans, Pseudomonas Infections, Antimicrobial strategies, Antimicrobial susceptibility testing, Respiratory Tract Infections
Abstract

In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17(th) European Cystic Fibrosis Society Basic Science Conference, held from 30 March to 2 April, 2022 in Albufeira, Portugal. Keynote lectures provided an update on the latest information regarding the phenomenon of antimicrobial resistance (AMR) in cystic fibrosis (CF). Traditional themes such as in vitro antibiotic susceptibility testing and its clinical value, AMR evolution in persistent Pseudomonas aeruginosa infection and the impact of biofilm on AMR were discussed. In addition, the report gives an overview on very recent AMR-related topics that include an ecological view of AMR in CF lung, referred to as resistome, and novel anti-infective approaches in preclinical or early clinical research such as antibiofilm drugs and bacteriophages. (c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Published
2022
Full Text
View/download PDF

4. Tobramycin safety and efficacy review article

Author

Carsten Schwarz, Giovanni Taccetti, Pierre-Regis Burgel, and Siobhain Mulrennan

Subjects
Pulmonary and Respiratory Medicine, Cystic Fibrosis, Administration, Inhalation, Pseudomonas aeruginosa, Tobramycin, Humans, Pseudomonas Infections, Anti-Bacterial Agents
Abstract

Pseudomonas aeruginosa is a common respiratory pathogen found in patients with cystic fibrosis (CF), contributing to increased hospitalization, more rapid progression of CF lung disease, and increased risk of death. Guidelines recommend early therapy using tobramycin inhaled solution (TIS) or inhaled powder (TIP). Both TIS and TIP treatment regimens have demonstrated positive clinical outcomes in efficacy and safety, including improvements in FEV

Published
2022
Full Text
View/download PDF

5. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Author

Bartolome R, Celli, Marc, Decramer, Jadwiga A, Wedzicha, Kevin C, Wilson, Alvar A, Agustí, Gerard J, Criner, William, MacNee, Barry J, Make, Stephen I, Rennard, Robert A, Stockley, Claus, Vogelmeier, Antonio, Anzueto, David H, Au, Peter J, Barnes, Pierre-Regis, Burgel, Peter M, Calverley, Ciro, Casanova, Enrico M, Clini, Christopher B, Cooper, Harvey O, Coxson, Daniel J, Dusser, Leonardo M, Fabbri, Bonnie, Fahy, Gary T, Ferguson, Andrew, Fisher, Monica J, Fletcher, Maurice, Hayot, John R, Hurst, Paul W, Jones, Donald A, Mahler, François, Maltais, David M, Mannino, Fernando J, Martinez, Marc, Miravitlles, Paula M, Meek, Alberto, Papi, Klaus F, Rabe, Nicolas, Roche, Frank C, Sciurba, Sanjay, Sethi, Nikos, Siafakas, Don D, Sin, Joan B, Soriano, James K, Stoller, Donald P, Tashkin, Thierry, Troosters, Geert M, Verleden, Johny, Verschakelen, Jorgen, Vestbo, John W, Walsh, George R, Washko, Robert A, Wise, Emiel F M, Wouters, Richard L, ZuWallack, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Queen's Medical Researche Institute, University of Edinburgh, Service de pneumologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Education for Health, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), Università degli Studi di Ferrara (UniFE), Department of Pulmonary Medicine, Leiden University Medical Center (LUMC), Service de Pneumologie et Soins Intensifs Respiratoires, Université Paris Descartes - Paris 5 (UPD5)-Hôpitaux Universitaires Paris Centre, Wythenshawe Hospital, Northwest Lung Centre, Brigham and Women's Hospital [Boston], Maastricht University [Maastricht], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Laval, Pulmonologie, RS: CAPHRI School for Public Health and Primary Care, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, MUMC+: MA Longziekten (3), and RS: CAPHRI - R5 - Optimising Patient Care

Subjects
Pulmonary and Respiratory Medicine, Chronic Obstructive, medicine.medical_specialty, Biomedical Research, Consensus, Statement (logic), therapies, MEDLINE, Socio-culturale, Pulmonary disease, Comorbidity, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Severity of Illness Index, Pulmonary Disease, Humans, Lung, Predictive Value of Tests, Pulmonary Disease, Chronic Obstructive, Respiratory Function Tests, Risk Factors, Risk Reduction Behavior, Treatment Outcome, medicine, COPD, Disease management (health), lcsh:RC705-779, clinical research, COPD, therapies, business.industry, Research statement, lcsh:Diseases of the respiratory system, Evidence-based medicine, medicine.disease, 3. Good health, Clinical research, clinical research, Family medicine, Physical therapy, Resource use, Research questions, business
Abstract

International audience; Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) research statement is to describe evidence related to diagnosis, assessment and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified. Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ ERS research statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes. @ERSpublications ATS/ERS statement: which types of research will have the greatest future impact on patient-centred outcomes in COPD? http://ow.ly/I54Hb

Published
2015
Full Text
View/download PDF

6. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease

Author

Bartolome R, Celli, Marc, Decramer, Jadwiga A, Wedzicha, Kevin C, Wilson, Alvar, Agustí, Gerard J, Criner, William, MacNee, Barry J, Make, Stephen I, Rennard, Robert A, Stockley, Claus, Vogelmeier, Antonio, Anzueto, David H, Au, Peter J, Barnes, Pierre-Regis, Burgel, Peter M, Calverley, Ciro, Casanova, Enrico M, Clini, Christopher B, Cooper, Harvey O, Coxson, Daniel J, Dusser, Leonardo M, Fabbri, Bonnie, Fahy, Gary T, Ferguson, Andrew, Fisher, Monica J, Fletcher, Maurice, Hayot, John R, Hurst, Paul W, Jones, Donald A, Mahler, François, Maltais, David M, Mannino, Fernando J, Martinez, Marc, Miravitlles, Paula M, Meek, Alberto, Papi, Klaus F, Rabe, Nicolas, Roche, Frank C, Sciurba, Sanjay, Sethi, Nikos, Siafakas, Don D, Sin, Joan B, Soriano, James K, Stoller, Donald P, Tashkin, Thierry, Troosters, Geert M, Verleden, Johny, Verschakelen, Jorgen, Vestbo, John W, Walsh, George R, Washko, Robert A, Wise, Emiel F M, Wouters, Richard L, ZuWallack, Richard L, Zuwallack, Lawrence Berkeley National Laboratory [Berkeley] (LBNL), Queen's Medical Researche Institute, University of Edinburgh, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University - Hospital of Modena and Reggio Emilia [Modena, Italy], Education for Health, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), The WALTHAM Centre for Pet Nutrition, Centre de Recherche, Université Laval [Québec] (ULaval), Arizona Respiratory Center, University of Ferrara at St. Anna Hospital, Department of Pulmonary Medicine, Leiden University Medical Center (LUMC), Service de Pneumologie et Soins Intensifs Respiratoires, Université Paris Descartes - Paris 5 (UPD5)-Hôpitaux Universitaires Paris Centre, Wythenshawe Hospital, Northwest Lung Centre, Fault Analysis Group, School of Geological Sciences, University College Dublin [Dublin] (UCD), Brigham and Women's Hospital [Boston], CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Laval, Pulmonologie, RS: CAPHRI School for Public Health and Primary Care, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, and RS: CAPHRI - R5 - Optimising Patient Care

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Biomedical Research, Statement (logic), [SDV]Life Sciences [q-bio], smoking cessation non invasive ventilation, MEDLINE, Socio-culturale, Pulmonary disease, Critical Care and Intensive Care Medicine, air flow obstruction, Pulmonary Disease, Chronic Obstructive, medicine, Humans, Organizational Objectives, Policy Making, oxygen theraphy, Societies, Medical, Positive-pressure ventilation, air flow obstruction, randomized controlled trial, oxygen theraphy, smoking cessation non invasive ventilation, lung function bode index, lung function bode index, COPD, Europe, Evidence-Based Medicine, United States, Medicine (all), business.industry, Research statement, Evidence-based medicine, medicine.disease, 3. Good health, Family medicine, randomized controlled trial, Physical therapy, Resource use, Research questions, Positive-pressure ventilation, business
Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. METHODS: Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarized, and then salient knowledge gaps were identified. RESULTS: Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. CONCLUSIONS: Great strides have been made in the diagnosis, assessment, and management of COPD as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS Research Statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered outcomes.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results